Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Metadata

Authors/Creators:
  • Jackson, G.H.
  • Davies, F.E.
  • Pawlyn, C.
  • Cairns, D.A.
  • Striha, A.
  • Collett, C.
  • Waterhouse, A.
  • Jones, J.R.
  • Kishore, B.
  • Garg, M.
  • Williams, C.D.
  • Karunanithi, K.
  • Lindsay, J.
  • Jenner, M.W.
  • Cook, G.
  • Kaiser, M.F.
  • Drayson, M.T.
  • Owen, R.G.
  • Russell, N.H.
  • Gregory, W.M.
  • Morgan, G.J.
Copyright, Publisher and Additional Information: © 2016 The American Society of Hematology.
Dates:
  • Published (online): 2 December 2016
  • Published: 2 December 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 19 Dec 2019 10:50
Last Modified: 19 Dec 2019 10:50
Status: Published
Publisher: American Society of Hematology
Refereed: Yes
Identification Number: https://doi.org/10.1182/blood.v128.22.1143.1143

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics